Ionis Pharmaceuticals (IONS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Ionis Pharmaceuticals (IONS) is Neutral.

The composite score behind that read is -0.08, weighing +0.27 of bullish evidence against -0.30 bearish.

Ionis Pharmaceuticals last closed at $45.28, +4.57% on the session.

Against the IVW growth benchmark the position is +3.77% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

19 graded predictions for IONS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Ionis Pharmaceuticals in the 10th percentile on return on equity, where 100 is best.

Ionis Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $7.20B.

StockMap tracks Ionis Pharmaceuticals as the 37th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Ionis Pharmaceuticals ranks 200th of 381 in the group, against a group median of -0.08.